{"id":"radium-223","rwe":[],"tags":[],"safety":{"safetySignals":[{"date":"","signal":"ANAEMIA","source":"FDA FAERS","actionTaken":"Reported 26 times"},{"date":"","signal":"PROSTATE CANCER","source":"FDA FAERS","actionTaken":"Reported 14 times"},{"date":"","signal":"THROMBOCYTOPENIA","source":"FDA FAERS","actionTaken":"Reported 14 times"},{"date":"","signal":"BACK PAIN","source":"FDA FAERS","actionTaken":"Reported 13 times"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"Reported 13 times"},{"date":"","signal":"PROSTATIC SPECIFIC ANTIGEN INCREASED","source":"FDA FAERS","actionTaken":"Reported 13 times"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"Reported 12 times"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"Reported 10 times"},{"date":"","signal":"BONE PAIN","source":"FDA FAERS","actionTaken":"Reported 9 times"},{"date":"","signal":"FEBRILE NEUTROPENIA","source":"FDA FAERS","actionTaken":"Reported 9 times"}],"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Other anticoagulants","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Lithium","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Other nephrotoxic agents","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Furosemide","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"Other loop diuretics","action":"Monitor","effect":"Increased risk of hypocalcemia"},{"drug":"Calcium supplements","action":"Avoid","effect":"Decreased efficacy of Radium-223"}],"commonSideEffects":[{"effect":"Anemia","drugRate":"93%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"36%","severity":"common","organSystem":""},{"effect":"Lymphocytopenia","drugRate":"72%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"25%","severity":"common","organSystem":""},{"effect":"Leukopenia","drugRate":"35%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"19%","severity":"common","organSystem":""},{"effect":"Thrombocytopenia","drugRate":"31%","severity":"common","organSystem":""},{"effect":"Neutropenia","drugRate":"18%","severity":"common","organSystem":""},{"effect":"Peripheral edema","drugRate":"13%","severity":"common","organSystem":""},{"effect":"Renal failure and impairment","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Pancytopenia","drugRate":"2%","severity":"common","organSystem":""}],"contraindications":["Pregnancy","Patients with compromised bone marrow reserve","Patients who experience life-threatening complications despite supportive care measures","Patients receiving concomitant chemotherapy","Patients receiving other systemic radioisotopes or hemibody external radiotherapy","Women who are or may become pregnant"],"specialPopulations":{"Pregnancy":"Xofigo can cause fetal harm when administered to a pregnant woman based on its mechanism of action. While there are no adequate and well-controlled studies in pregnant women, Xofigo is contraindicated in women who are or may become pregnant during treatment with Xofigo.","Geriatric use":"Not mentioned in the text.","Pediatric use":"The safety and efficacy of Xofigo in pediatric patients have not been established.","Renal impairment":"No dedicated renal impairment trial for Xofigo has been conducted. Based on subgroup analyses in the randomized clinical trial, dose adjustment is not needed in patients with existing mild (creatinine clearance [CrCl] 60 to 89 mL/min) or moderate (CrCl 30 to 59 mL/min) renal impairment. No dose adjustment can be recommended for patients with severe renal impairment (CrCl less than 30 mL/min) due to limited data available (n = 2).","Hepatic impairment":"No dedicated hepatic impairment trial for Xofigo has been conducted. Since radium-223 is neither metabolized by the liver nor excreted in the bile, dose adjustments are not needed in patients with mild hepatic impairment. No dose adjustments can be recommended for patients with moderate or severe hepatic impairment due to lack of clinical data."},"seriousAdverseEvents":[{"effect":"Lymphocytopenia (Grade 3-4)","drugRate":"20%","severity":"serious"},{"effect":"Anemia (Grade 3-4)","drugRate":"6%","severity":"serious"},{"effect":"Thrombocytopenia (Grade 3-4)","drugRate":"6%","severity":"serious"},{"effect":"Leukopenia (Grade 3-4)","drugRate":"3%","severity":"serious"},{"effect":"Neutropenia (Grade 3-4)","drugRate":"2%","severity":"serious"},{"effect":"Nausea (Grade 3-4)","drugRate":"2%","severity":"serious"},{"effect":"Diarrhea (Grade 3-4)","drugRate":"2%","severity":"serious"},{"effect":"Vomiting (Grade 3-4)","drugRate":"2%","severity":"serious"},{"effect":"Peripheral edema (Grade 3-4)","drugRate":"2%","severity":"serious"},{"effect":"Renal failure and impairment (Grade 3-4)","drugRate":"1%","severity":"serious"}]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=radium-223","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:50:58.961789+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Radium-223","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:51:07.043259+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:51:05.389665+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:50:58.980335+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=radium-223","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:51:06.154538+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2107816/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:51:06.947671+00:00"}},"offLabel":[],"timeline":[{"date":"1905-01-01","type":"neutral","_source":"Wikipedia","milestone":"Discovery of Radium-223","regulator":"none"}],"aiSummary":"Radium-223, developed by Pfizer Inc., is an alpha-emitting isotope used to treat Castration-Resistant Prostate Cancer with Bone Metastases. It mimics calcium and forms complexes with hydroxyapatite at areas of increased bone turnover. This radiopharmaceutical takes advantage of its chemical similarity to calcium. Radium-223 has shown clinical differentiation in treating metastatic cancers in bone. Its commercial significance lies in its ability to target cancer cells in bone. There are no notable pipeline developments for Radium-223.","brandName":"Radium-223","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Bone cells","novelty":"First-in-class","modality":"Small molecule","drugClass":"Radiopharmaceutical","explanation":"","oneSentence":"","technicalDetail":"Radium-223 is an alpha-emitting isotope with a half-life of 11.435 days. It targets cancer cells in bone by forming complexes with hydroxyapatite. This process takes advantage of the chemical similarity between radium-223 and calcium. Radium-223 dichloride is a radiopharmaceutical used to treat metastatic cancers in bone."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_wikipedia":{"title":"Radium-223","extract":"Radium-223 is an alpha-emitting isotope of radium with half-life 11.435 days. It was discovered in 1905 by T. Godlewski, a Polish chemist from Kraków, and was historically known as actinium X (AcX). Radium-223 dichloride is an alpha particle-emitting radiotherapy drug that mimics calcium and forms complexes with hydroxyapatite at areas of increased bone turnover. The principal use of radium-223, as a radiopharmaceutical to treat metastatic cancers in bone, takes advantage of its chemical similarity to calcium, and the short range of the alpha radiation it emits.","wiki_medical_uses":"==Medical uses==\n\n| MedlinePlus       =\n| DailyMedID        = Xofigo\n| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_category=\n| routes_of_administration = Intravenous\n| ATC_prefix        = V10\n| ATC_suffix        = XX03\n\n| legal_AU = S4\n| legal_AU_comment = \n| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->\n| legal_US = Rx-only\n| legal_US_comment = \n| legal_EU = Rx-only\n| legal_EU_comment = \n| legal_status      = \n\n<!-- Pharmacokinetic data -->\n| bioavailability   =\n| protein_bound     =\n| metabolism        =\n| elimination_half-life =\n| excretion         =\n\n<!-- Identifiers -->\n| CAS_number_Ref = \n| CAS_number        = 444811-40-9\n| PubChem           = 6335825\n| ChEBI = 74895\n| DrugBank_Ref = \n| DrugBank          =\n| ChemSpiderID_Ref = \n| ChemSpiderID = none\n| UNII_Ref = \n| UNII = RJ00KV3VTG\n| KEGG = D10398\n\n<!-- Chemical data -->\n| IUPAC_name        = Radium-223 chloride\n| chemical_formula  = <sup>223</sup>RaCl<sub>2</sub>\n| molecular_weight  = 296.91\n| molecular_weight_comment = g/mol\n}}\n\nThe pharmaceutical product and medical use of radium-223 against skeletal metastases was invented by Roy H. Larsen, Gjermund Henriksen and Øyvind S. Bruland and has been developed by the former Norwegian company Algeta ASA, in a partnership with Bayer, under the trade name Xofigo (formerly Alpharadin), and is distributed as a "},"commercial":{"revenueYear":2024,"annualCostUS":"","annualRevenue":400,"genericStatus":"Generic — off-patent","revenueSource":"Verified: Bayer AR","currentRevenue":"","revenueCurrency":"USD","patientPopulation":"Generic — multiple manufacturers","peakSalesEstimate":"","revenueConfidence":"verified"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=radium-223","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=radium-223","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://en.wikipedia.org/wiki/radium-223","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":6,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":7,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:51:08.877776+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Lupron Depot","company":"Takeda","advantage":"Hormone deprivation treatment for palliative care of advanced prostate cancer"},{"name":"Lynparza","company":"AstraZeneca","advantage":"PARP inhibitor for treatment of ovarian, breast, pancreatic, and prostate cancer"},{"name":"Zytiga","company":"Janssen Pharmaceuticals","advantage":"Oral androgen receptor inhibitor for treatment of prostate cancer"},{"name":"Casodex","company":"AstraZeneca","advantage":"Nonsteroidal antiandrogen for treatment of prostate cancer"},{"name":"Xtandi","company":"Astellas Pharma","advantage":"Oral androgen receptor inhibitor for treatment of prostate cancer"},{"name":"Bicalutamide","company":"AstraZeneca","advantage":"Nonsteroidal antiandrogen for treatment of prostate cancer"},{"name":"Camcevi","company":"Takeda","advantage":"Hormone deprivation treatment for palliative care of advanced prostate cancer"}],"genericName":"radium-223","indications":{"approved":[{"name":"Castration-Resistant Prostate Cancer, Bone Metastases","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04090398","phase":"PHASE2","title":"Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-04","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone","enrollment":70},{"nctId":"NCT04071236","phase":"PHASE1, PHASE2","title":"Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-10-14","conditions":"Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes","enrollment":90},{"nctId":"NCT04071223","phase":"PHASE2","title":"Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-29","conditions":"Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma","enrollment":134},{"nctId":"NCT07477756","phase":"","title":"A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-09-04","conditions":"Prostate Cancer","enrollment":1247},{"nctId":"NCT04206319","phase":"PHASE2","title":"Radium-223 in Biochemically Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-22","conditions":"Biochemical Recurrent Prostate Cancer","enrollment":19},{"nctId":"NCT04109729","phase":"PHASE1","title":"Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2020-09-16","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":39},{"nctId":"NCT04597125","phase":"PHASE4","title":"RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2020-11-09","conditions":"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","enrollment":654},{"nctId":"NCT03574571","phase":"PHASE3","title":"A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-06-19","conditions":"Prostate Cancer","enrollment":732},{"nctId":"NCT03344211","phase":"PHASE2","title":"Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2018-11-21","conditions":"Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer","enrollment":30},{"nctId":"NCT00699751","phase":"PHASE3","title":"A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-06-12","conditions":"Hormone Refractory Prostate Cancer, Bone Metastases","enrollment":921},{"nctId":"NCT03317392","phase":"PHASE1, PHASE2","title":"Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-02-04","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":145},{"nctId":"NCT04489719","phase":"","title":"Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2021-04-16","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma","enrollment":48},{"nctId":"NCT04704505","phase":"PHASE2","title":"Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-04-28","conditions":"Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma, Castration-resistant","enrollment":47},{"nctId":"NCT05701007","phase":"","title":"Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-02-13","conditions":"Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":1083},{"nctId":"NCT07221825","phase":"NA","title":"Low-Count Quantitative SPECT for Men Treated With Radium-223","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-01","conditions":"Prostate Cancer, Cancer of the Prostate","enrollment":38},{"nctId":"NCT05133440","phase":"PHASE2","title":"A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-11-12","conditions":"Prostate Cancer","enrollment":12},{"nctId":"NCT05924672","phase":"PHASE2","title":"Efficacy of Ra-223 in PSMA PET Optimally Selected Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-08-30","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Stage IVB Prostate Cancer AJCC v8","enrollment":2},{"nctId":"NCT04037358","phase":"PHASE2","title":"RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-08-09","conditions":"Prostate Cancer","enrollment":64},{"nctId":"NCT02141438","phase":"","title":"Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-08-20","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":1472},{"nctId":"NCT03737370","phase":"PHASE1","title":"Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Tufts Medical Center","startDate":"2018-01-30","conditions":"Metastatic Castrate Resistant Prostate Cancer","enrollment":43},{"nctId":"NCT04521361","phase":"PHASE1","title":"A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-11-16","conditions":"Bone Metastatic Castration-resistant Prostate Cancer","enrollment":46},{"nctId":"NCT02194842","phase":"PHASE3","title":"Phase III Radium 223 mCRPC-PEACE III","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2015-10","conditions":"Prostate Cancer","enrollment":446},{"nctId":"NCT04951817","phase":"NA","title":"68Ga-PSMA PET/CT for Ra223 Assessment","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2022-03-02","conditions":"Metastatic Prostate Cancer","enrollment":52},{"nctId":"NCT06401980","phase":"PHASE2","title":"Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2024-10-22","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":162},{"nctId":"NCT02803437","phase":"","title":"Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-07-21","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":334},{"nctId":"NCT06659926","phase":"NA","title":"The Radium-select Study","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2025-02-24","conditions":"mCRPC, Male Urogenital Diseases","enrollment":60},{"nctId":"NCT03361735","phase":"PHASE2","title":"Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-08-29","conditions":"Prostate Adenocarcinoma","enrollment":25},{"nctId":"NCT03304418","phase":"PHASE2","title":"Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone","status":"COMPLETED","sponsor":"University of Utah","startDate":"2018-02-27","conditions":"Prostate Cancer Metastatic to Bone","enrollment":20},{"nctId":"NCT03076203","phase":"PHASE1","title":"Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2017-09-22","conditions":"Prostate Carcinoma Metastatic to the Bone, Stage IV Prostate Adenocarcinoma, Hormone-refractory Prostate Cancer","enrollment":14},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":750},{"nctId":"NCT03093428","phase":"PHASE2","title":"Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-06-09","conditions":"Prostate Cancer","enrollment":45},{"nctId":"NCT02312960","phase":"PHASE4","title":"Radium-223 Dichloride Long-term Follow-up Program","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-12-18","conditions":"Neoplasm Metastasis / Bone and Bones","enrollment":255},{"nctId":"NCT06389097","phase":"","title":"SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-02-03","conditions":"Prostate Cancer, Advanced Cancer","enrollment":80},{"nctId":"NCT02043678","phase":"PHASE3","title":"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-30","conditions":"Prostatic Neoplasms","enrollment":806},{"nctId":"NCT05383079","phase":"PHASE1, PHASE2","title":"Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2022-09-13","conditions":"Metastatic Castration-resistant Prostate Cancer, MCRPC, Prostate Cancer","enrollment":36},{"nctId":"NCT03002220","phase":"PHASE2","title":"Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status","status":"COMPLETED","sponsor":"MedSIR","startDate":"2016-12-21","conditions":"Prostate Cancer","enrollment":52},{"nctId":"NCT03707184","phase":"PHASE2","title":"Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone","status":"COMPLETED","sponsor":"University of Utah","startDate":"2018-10-02","conditions":"Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer","enrollment":17},{"nctId":"NCT03996473","phase":"PHASE1","title":"Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases","status":"TERMINATED","sponsor":"Bayer","startDate":"2020-03-06","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":8},{"nctId":"NCT03230734","phase":"PHASE2","title":"Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2017-09-01","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":70},{"nctId":"NCT06585007","phase":"PHASE3","title":"Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-12-19","conditions":"Castration-resistant Prostate Cancer, Oligoprogressive","enrollment":246},{"nctId":"NCT04232761","phase":"","title":"Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-07-07","conditions":"Castration-resistant Prostate Cancer","enrollment":194},{"nctId":"NCT04587427","phase":"","title":"A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-05-15","conditions":"Bone Metastatic Castration-resistant Prostate Cancer","enrollment":1067},{"nctId":"NCT03315260","phase":"","title":"Treatment Satisfaction With Ra-223 in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-04-11","conditions":"Prostatic Neoplasms","enrollment":85},{"nctId":"NCT02903160","phase":"PHASE2","title":"Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2017-01-13","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT03432949","phase":"PHASE4","title":"Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2018-02-23","conditions":"Metastatic Prostate Cancer","enrollment":24},{"nctId":"NCT03677076","phase":"","title":"Clonal Emergence and Regression During Radium-223 Therapy for Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2019-03-04","conditions":"Prostate Cancer","enrollment":14},{"nctId":"NCT04256993","phase":"","title":"PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-02-15","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1434},{"nctId":"NCT02258451","phase":"PHASE2","title":"Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-04","conditions":"Breast Neoplasms","enrollment":283},{"nctId":"NCT00337155","phase":"PHASE2","title":"BAY88-8223, Dose Finding Study in Patients With HRPC","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-05","conditions":"Prostate Cancer, Neoplasm Metastasis","enrollment":122},{"nctId":"NCT04681144","phase":"","title":"A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-04-08","conditions":"Prostate Cancer","enrollment":103},{"nctId":"NCT05301062","phase":"","title":"A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels","status":"TERMINATED","sponsor":"Bayer","startDate":"2022-09-15","conditions":"Metastatic Castration-resistant Prostate Cancer, Bone Metastases","enrollment":8},{"nctId":"NCT05771896","phase":"PHASE3","title":"Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC","status":"WITHDRAWN","sponsor":"GenesisCare USA","startDate":"2023-09","conditions":"Metastatic Prostate Cancer","enrollment":0},{"nctId":"NCT00667199","phase":"PHASE2","title":"BAY88-8223, Does Response Study in HRPC Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-05-30","conditions":"Hormone Refractory Prostate Cancer, Bone Metastases","enrollment":100},{"nctId":"NCT03223727","phase":"","title":"Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2015-10-30","conditions":"Prostate Cancer Metastatic, Bone Metastases","enrollment":100},{"nctId":"NCT02278055","phase":"PHASE2","title":"Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-10-08","conditions":"Metastatic Prostate Cancer, Pain","enrollment":29},{"nctId":"NCT02225704","phase":"PHASE2","title":"Radium-223 in Combination With Enzalutamide","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2015-06-03","conditions":"Prostate Cancer","enrollment":45},{"nctId":"NCT04833517","phase":"","title":"Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)","status":"UNKNOWN","sponsor":"Universität des Saarlandes","startDate":"2016-01-01","conditions":"Prostate Cancer Metastatic, Castration Resistant Prostatic Cancer, Advanced Prostate Carcinoma","enrollment":500},{"nctId":"NCT03247010","phase":"","title":"Bone Marrow Suppression and Recovery During Radionuclide Treatment","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2017-06-20","conditions":"Castration-resistant Prostate Cancer","enrollment":68},{"nctId":"NCT04237584","phase":"PHASE3","title":"A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients","status":"TERMINATED","sponsor":"MANA RBM","startDate":"2020-06-30","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":23},{"nctId":"NCT02346526","phase":"PHASE2","title":"A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2015-04","conditions":"Prostate Cancer, Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer Metastatic to Bone","enrollment":22},{"nctId":"NCT02582749","phase":"PHASE2","title":"Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases","status":"TERMINATED","sponsor":"Ajjai Alva, MD","startDate":"2016-04","conditions":"Prostate Cancer, Bone Metastases, Prostate Neoplasms","enrollment":16},{"nctId":"NCT04281147","phase":"","title":"Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-02-24","conditions":"Prostate Cancer","enrollment":4301},{"nctId":"NCT04193657","phase":"","title":"Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2019-10-25","conditions":"Metastatic Prostate Cancer","enrollment":91},{"nctId":"NCT02715583","phase":"EARLY_PHASE1","title":"C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2016-03","conditions":"Prostate Cancer Patients","enrollment":6},{"nctId":"NCT03223597","phase":"","title":"Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2015-01-17","conditions":"Prostate Cancer Metastatic, Bone Metastases","enrollment":300},{"nctId":"NCT04516161","phase":"","title":"EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-08-03","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":1180},{"nctId":"NCT02135484","phase":"NA","title":"Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-09-19","conditions":"Prostate Cancer","enrollment":27},{"nctId":"NCT03896984","phase":"","title":"Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-03-18","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC)","enrollment":346},{"nctId":"NCT02450812","phase":"","title":"Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-05-28","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":86},{"nctId":"NCT02398526","phase":"","title":"Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-03-19","conditions":"Castration-Resistant Prostatic Cancer","enrollment":363},{"nctId":"NCT02366130","phase":"PHASE2","title":"Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-02-11","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT03062254","phase":"PHASE2","title":"Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy","status":"COMPLETED","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2018-03-22","conditions":"Prostate Cancer","enrollment":14},{"nctId":"NCT03305224","phase":"PHASE2","title":"The Combination Therapy With Ra-223 and Enzalutamide","status":"UNKNOWN","sponsor":"Taro Iguchi, MD, PHD","startDate":"2017-10-27","conditions":"Castration-resistant Prostate Cancer, Bone Metastases","enrollment":10},{"nctId":"NCT04995614","phase":"","title":"Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2017-04-01","conditions":"Castrate Resistant Prostate Cancer, Bone Metastases","enrollment":122},{"nctId":"NCT02463799","phase":"PHASE2","title":"Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-02-22","conditions":"Prostate Cancer","enrollment":36},{"nctId":"NCT02981797","phase":"","title":"Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2015-07-22","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":10},{"nctId":"NCT02283749","phase":"PHASE2","title":"BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases","status":"COMPLETED","sponsor":"Angela Taber MD","startDate":"2015-09","conditions":"Non Small Cell Lung Cancer With Bone Metastatses","enrollment":5},{"nctId":"NCT01833520","phase":"PHASE1, PHASE2","title":"Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-10-16","conditions":"Sarcoma","enrollment":18},{"nctId":"NCT03458559","phase":"PHASE3","title":"Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2018-05-16","conditions":"Prostate Cancer Metastatic to Bone","enrollment":402},{"nctId":"NCT03419442","phase":"","title":"Multi-academic Center Study of Xofigo Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-12-03","conditions":"Prostate Cancer, Castration Resistant","enrollment":150},{"nctId":"NCT02258464","phase":"PHASE2","title":"Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Bayer","startDate":"2015-03-02","conditions":"Breast Neoplasms","enrollment":99},{"nctId":"NCT03563014","phase":"","title":"A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-07-31","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":164},{"nctId":"NCT02899104","phase":"","title":"Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-06-15","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":200},{"nctId":"NCT02406521","phase":"PHASE1","title":"Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-04","conditions":"Metastatic Renal Cell Carcinoma","enrollment":30},{"nctId":"NCT02928029","phase":"PHASE1, PHASE2","title":"Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma","status":"TERMINATED","sponsor":"Bayer","startDate":"2017-02-10","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT02925702","phase":"","title":"PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.","status":"UNKNOWN","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","startDate":"2016-02","conditions":"Advanced Prostate Cancer, Castration Resistant, Radium 223","enrollment":161},{"nctId":"NCT02964988","phase":"PHASE2","title":"uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer","status":"TERMINATED","sponsor":"Rigshospitalet, Denmark","startDate":"2017-01","conditions":"Prostate Cancer Metastatic, Bone Metastases","enrollment":17},{"nctId":"NCT04110782","phase":"","title":"Radical Prostatectomy and External Beam Radiotherapy in mCRPC With 223Radium-dicloride (RaProRad)","status":"UNKNOWN","sponsor":"Azienda Policlinico Umberto I","startDate":"2015-09","conditions":"Prostate Cancer","enrollment":400},{"nctId":"NCT02814669","phase":"PHASE1","title":"Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-09-23","conditions":"Castrate-Resistant Prostate Cancer","enrollment":45},{"nctId":"NCT03011749","phase":"NA","title":"Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients","status":"TERMINATED","sponsor":"Rigshospitalet, Denmark","startDate":"2017-01","conditions":"Metastatic Prostate Carcinoma","enrollment":6},{"nctId":"NCT02034552","phase":"PHASE2","title":"A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-07","conditions":"Prostatic Neoplasms","enrollment":68},{"nctId":"NCT02023697","phase":"PHASE2","title":"Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-10","conditions":"Prostatic Neoplasms","enrollment":391},{"nctId":"NCT02456571","phase":"","title":"CTC Immune Checkpoint","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-11","conditions":"Prostate Cancer","enrollment":38},{"nctId":"NCT02390934","phase":"PHASE2","title":"Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2014-10-01","conditions":"Thyroid Cancer","enrollment":13},{"nctId":"NCT03368989","phase":"","title":"The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2014-02-11","conditions":"Bony Metastases From Castrate Refractory Prostate Cancer","enrollment":21},{"nctId":"NCT03325127","phase":"","title":"Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2017-10-30","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":0},{"nctId":"NCT03208712","phase":"EARLY_PHASE1","title":"Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2017-11-01","conditions":"Urothelial Carcinoma","enrollment":1},{"nctId":"NCT01810770","phase":"PHASE3","title":"Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-03-26","conditions":"Prostatic Neoplasms","enrollment":243},{"nctId":"NCT02518698","phase":"","title":"Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-08-31","conditions":"Prostate Cancer","enrollment":1163},{"nctId":"NCT02204943","phase":"EARLY_PHASE1","title":"Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Duke University","startDate":"2015-05-06","conditions":"Bone Metastatic Castration-Resistant Prostate Cancer","enrollment":20}],"_emaApprovals":[{"date":"","name":"Radium-223","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL2107816","moleculeType":"Small molecule","molecularWeight":"293.92"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2107816","pubchemSID":"114465840"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"notes":"","period":"1905-present","_source":"Wikipedia","companyName":"T. Godlewski","relationship":"Originator"}],"publicationCount":1035,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-08 13:59:10.742531+00","biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 28","pmid":"41903088","title":"Clinical efficacy of radium-223 in simulating real-world clinical practice: a meta-analysis.","journal":"Annals of nuclear medicine"},{"date":"2026 Feb 28","pmid":"41828508","title":"Alpha and Beta Emitters in Translational Nuclear Medicine: Clinical Advances, Challenges, and Future Direction.","journal":"International journal of molecular sciences"},{"date":"2026 Mar 9","pmid":"41801523","title":"Predictive value of interim ¹¹C-choline PET/CT for response to radium-223 in metastatic castration-resistant prostate cancer.","journal":"EJNMMI research"},{"date":"2026 Mar 16","pmid":"41778996","title":"Synthesis, Characterization, and Evaluation of Chelators for Radium-223.","journal":"Inorganic chemistry"},{"date":"2026 Mar 3","pmid":"41774055","title":"Real-world effectiveness and safety of radium-223 therapy in castration-resistant prostate cancer with bone metastases.","journal":"Asian journal of andrology"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":4,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":13,"withResults":6},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:51:08.877776+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}